Elicio Therapeutics, Inc. (ELTX)
1.53
+0.03
(+2.00%)
USD |
NASDAQ |
Nov 20, 10:01
Elicio Therapeutics Free Cash Flow : -36.99M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -36.99M |
| June 30, 2026 | -37.71M |
| March 31, 2026 | -38.49M |
| December 31, 2025 | -36.97M |
| September 30, 2025 | -38.94M |
| June 30, 2025 | -35.13M |
| March 31, 2025 | -35.15M |
| December 31, 2024 | -37.16M |
| September 30, 2024 | -38.26M |
| June 30, 2024 | -36.22M |
| March 31, 2024 | -36.73M |
| December 31, 2023 | -32.76M |
| Date | Value |
|---|---|
| September 30, 2023 | -30.24M |
| June 30, 2023 | -30.39M |
| March 31, 2023 | -15.34M |
| December 31, 2022 | -22.83M |
| September 30, 2022 | -29.86M |
| June 30, 2022 | -39.73M |
| March 31, 2022 | -56.09M |
| December 31, 2021 | -53.02M |
| September 30, 2021 | -18.05M |
| June 30, 2021 | -24.73M |
| March 31, 2021 | -26.77M |
| December 31, 2020 | -22.93M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Lineage Cell Therapeutics, Inc. | -26.46M |
| Armata Pharmaceuticals, Inc. | -26.86M |
| Voyager Therapeutics, Inc. | -109.83M |
| Black Diamond Therapeutics, Inc. | -33.32M |
| Invivyd, Inc. | -134.11M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -10.36M |
| Cash from Financing (Quarterly) | 17.78M |
| Free Cash Flow Per Share (Quarterly) | -0.3942 |
| Free Cash Flow to Equity (Quarterly) | -10.21M |
| Free Cash Flow to Firm (Quarterly) | -9.948M |
| Free Cash Flow Yield | -85.40% |